Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 3 november 2025, 17.45 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 9.692 eigen aandelen ingekocht werden op Euronext Brussel tussen 30 en 31 oktober 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)30/10/202569264,9164,5565,0044.91831/10/20259.00062,9562,6065,00566.533TOTAAL9.69263,0962,5065,00611.451 Als gevolg van aankopen die zijn ge...
                                            Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 3 November 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports the purchase of 9,692 Melexis shares on Euronext Brussels in the period from 30 to 31 October 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)30/10/202569264.9164.5565.0044,91831/10/20259,00062.9562.6065.00566,533TOTAL9,69263.0962.5065.00611,451 As a result of purchases made since the launch of the share b...
                                                                                
                                                                                Adyen: 3Q25 results – solid net revenue, FY25 guidance reiterated. Aedifica: Guidance raised, positive tenant trends and good portfolio valuation. Ageas: China Taiping Life 3Q25 Solvency much lower, remains solid. Allfunds Group PLC: Strong flows. ASM International: 3Q25 results - disappointing orders, much better margins. Corbion: Iron wills and nerves of steel. Lotus Bakeries: peer Mondelez 3Q25 results. Melexis: 3Q25 results, ongoing gross margin pressure. Staffing: Dutch figs...
                                                                                After a good set of 3Q25 results with gross profit margin a little below our and CSS forecasts but EBIT margin nicely above expectations due to ongoing fixed cost control. We feel comfortable with our € 78 TP and Accumulate rating as for FY25, Melexis expects sales to be in the range of € 840 to € 845m (KBCSe € 839m, CSS € 842.3m). So Melexis expects 4Q25 sales in the range of € 215 to 220m (KBCSe € 216.2m, CSS € 218.6m). Melexis is also guiding for FY25 a gross profit margin around 39% (KBCSe 3...
    
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.